Aktuellt
SENASTE
Redeye raises its full-year sales estimates for 2022E from EUR 7.6m to EUR 10.2m but lower our 2023-2024 estimates by 7-20% following the report and licensing agreement with Magnus Medical. We continue to see good prospects in Nexstim but argue that the slowing growth in the NBT segment and upcoming licensing period add some uncertainty to the case for growth in the upcoming years. We slightly lower our base case to SEK 62.5 per share.
LÄS MER
